Bridgepoint Development Capital To Acquire Quotient Clinical

December 13, 2013

Applied Clinical Trials

Quotient Clinical has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital.

Quotient Clinical has been acquired from the Quotient Bioresearch Group by Bridgepoint Development Capital.

Quotient's platform, which "offers an integrated approach to formulation development, 'real-time' drug product manufacturing and clinical testing," has been proven to reduce the time and cost of early stage drug development. A global company, Quotient has two primary facilities in the UK, and more that 3/4 of its revenues are from customers in the US or mainland Europe.

The financial details of the acquisition were undisclosed.

Read the full release here.